1 hour ago
GlaxoSmithKline Pharmaceuticals Ltd on Monday (February 9) reported a 28.6% year-on-year increase in net profit for the third quarter, with profit rising to ₹295.6 crore compared with ₹229.8 crore in the same period last year.
Revenue for the quarter grew 9.7% to ₹1,041 crore from ₹949.4 crore a year earlier. EBITDA increased 27.2% year-on-year to ₹371.1 crore from ₹291.8 crore, while operating margin improved to 35.6% from 30.7%.
The company said that during the quarter and nine months ended December 31, 2025, employee benefits expense increased by ₹11.82 crore following the Government of India’s notification of the four Labour Codes on November 21, 2025. The incremental impact arose primarily due to a change in the wage definition, based on an actuarial valuation.
Also Read: Market holds opening gains; Sensex up 485 points, Nifty reclaims 25,800
The company stated that it continues to monitor the finalisation of Central and State Rules and related clarifications and will account for further developments as required.
For the nine months ended December 31, 2025, GlaxoSmithKline Pharmaceuticals Ltd reported a total income of ₹2,935.78 crore, up from ₹2,880.09 crore in the corresponding period last year.
Total expenses for the same period stood at ₹1,923.49 crore, slightly lower than ₹1,983.47 crore in the previous year’s nine months. The company recorded a profit before tax of ₹1,032.91 crore, an increase from ₹901.31 crore in the same period last year.
Also Read: Kaveri Seed sees sales surge, profits dip as costs weigh despite better efficiency
The net profit for the nine months was ₹758.12 crore, significantly higher than the ₹664.71 crore reported in the corresponding period of 2024. Shares of GlaxoSmithKline Pharmaceuticals Ltd, today (Feb 9) closed at ₹2,515 on the NSE, up ₹31 or 1.25%, on NSE.
